Gene · 8030
Papers1,913
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 1,913
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study. | Cancer Med | 2023 | 37326363 | PubTator, text mining | PubMed |
| Renal C4d is a potential biomarker of disease activity and severity in pediatric lupus nephritis patients. | Front Pediatr | 2023 | 37325343 | PubTator, text mining | PubMed |
| Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer. | Clin Transl Med | 2023 | 37317665 | PubTator, text mining | PubMed |
| Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial. | JCO Precis Oncol | 2023 | 37315261 | PubTator, text mining | PubMed |
| Compromised nonsense-mediated RNA decay results in truncated RNA-binding protein production upon DUX4 expression. | Cell Rep | 2023 | 37314931 | PubTator, text mining | PubMed |
| Molecular testing raises thyroid nodule fine needle aspiration diagnostic value. | Endocr Connect | 2023 | 37310413 | PubTator, text mining | PubMed |
| Genomics driven precision oncology in advanced biliary tract cancer improves survival. | Neoplasia | 2023 | 37267699 | PubTator, text mining | PubMed |
| FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors. | Clin Cancer Res | 2023 | 37265412 | PubTator, text mining | PubMed |
| Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report. | Anticancer Drugs | 2023 | 37265026 | PubTator, text mining | PubMed |
| Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. | Mol Oncol | 2023 | 37243883 | PubTator, text mining | PubMed |
| The Real Post-Operative Range of Motion Differs from the Virtual Pre-Operative Planned Range of Motion in Reverse Shoulder Arthroplasty. | J Pers Med | 2023 | 37240935 | PubTator, text mining | PubMed |
| Antitumor Effects of Cannabis sativa Bioactive Compounds on Colorectal Carcinogenesis. | Biomolecules | 2023 | 37238634 | PubTator, text mining | PubMed |
| PTC-MAS: A Deep Learning-Based Preoperative Automatic Assessment of Lymph Node Metastasis in Primary Thyroid Cancer. | Diagnostics (Basel) | 2023 | 37238205 | PubTator, text mining | PubMed |
| Loss of the emei tumor suppressor promotes tumorigenesis via the JNK and Hippo pathway. | Genes Dis | 2023 | 37223519 | PubTator, text mining | PubMed |
| Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement. | Cancer Res Treat | 2023 | 37218138 | PubTator, text mining | PubMed |
| The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy. | Front Immunol | 2023 | 37215134 | PubTator, text mining | PubMed |
| Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review. | Transl Lung Cancer Res | 2023 | 37197619 | PubTator, text mining | PubMed |
| Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics. | Diagnostics (Basel) | 2023 | 37189577 | PubTator, text mining | PubMed |
| RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients. | Pathol Oncol Res | 2023 | 37188126 | PubTator, text mining | PubMed |
| Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib. | Front Oncol | 2023 | 37182165 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8030/papers?page=13